Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor
< 1 minute read
Sep. 18, 2021
Linrodostat: An Oral Selective IDO1 Dioxygenase Inhibitor
linrodostat
oral sel. IDO1 dioxygenase inhibitor 100 mg QD, in I/O combo studies for cancer acts on apo-IDO1 displacing heme co-factor Mol. Cancer Ther., Dec. 9, 2020 BMS, Princeton, NJ / Flexus, San Carlos, CA